Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Oracle Corporation (ORCL) Price & Performance

ACADIA Pharmaceuticals Inc.Trade

Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Oracle Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while Oracle Corporation trades at $148.3 (market cap $419.05B). The key difference: Oracle Corporation is far larger — about 82.7× ACADIA Pharmaceuticals Inc.'s market cap, and Oracle Corporation pays a 1.37% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.

	ACAD	ORCL
Market Cap	$5.07B	$419.05B
Sector	Health	Technology
52-Week High	$29.41	$328.33
52-Week Low	$20.06	$114.99
Enterprise Value	$4.19B	$548.30B
Dividend Yield	—	1.37%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

No Aura AI signal available yet.

Oracle Corporation

Oracle Corporation (ORCL) trades at $151.04, up 2.79% with strong technical momentum. The stock shows robust fundamentals with 21.67% net profit margin and consistent earnings beats in recent quarters. Oracle's AI infrastructure positioning and partnership with OpenAI have driven investor optimism, though RSI levels suggest potential overbought conditions. The company maintains solid cash flow generation with $20.82B from operations in 2025.

Oracle presents a compelling growth story with AI-driven revenue acceleration and strong analyst support (65% buy ratings). Key risks include high valuation multiples and significant debt load. The consensus price target of $252.44 implies substantial upside, but investors should monitor execution on AI investments and competitive pressures in cloud infrastructure.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ACAD

Immunic appoints Elena Ridloff to board ahead of key Phase 3 MS trial data and potential commercialization.PRNewsWire · 1 day agoBullish ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.Andrew Wynn · 2 days agoBullish View details →

ORCL

Nebius shares jump 3.7% as NVIDIA backs $500B AI cloud fund, Oracle slips amid competitive pressure.24/7 Wall Street · 21 hours agoBullish Oracle poised for 40% gain as AI cloud growth and backlog surge drive bullish outlook24/7 Wall Street · 1 day agoBullish Oracle launches AI-powered HR tools in Fusion Cloud to boost workforce development and talent management.PRNewsWire · 1 day agoBullish View details →

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.